Wall Street analysts forecast that Mersana Therapeutics Inc (NASDAQ:MRSN) will post $3.57 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Mersana Therapeutics’ earnings. The lowest sales estimate is $3.00 million and the highest is $4.15 million. The company is expected to issue its next quarterly earnings report on Thursday, February 22nd.
On average, analysts expect that Mersana Therapeutics will report full year sales of $3.57 million for the current year, with estimates ranging from $17.28 million to $18.43 million. For the next fiscal year, analysts expect that the business will report sales of $16.58 million per share. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Mersana Therapeutics.
Several equities analysts have issued reports on the stock. HC Wainwright assumed coverage on shares of Mersana Therapeutics in a report on Thursday. They issued a “buy” rating on the stock. ValuEngine upgraded shares of Mersana Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research downgraded shares of Mersana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Mersana Therapeutics presently has an average rating of “Buy” and a consensus price target of $23.67.
Mersana Therapeutics (NASDAQ:MRSN) opened at $15.36 on Friday. Mersana Therapeutics has a 1-year low of $12.45 and a 1-year high of $21.01.
WARNING: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/02/18/mersana-therapeutics-inc-mrsn-expected-to-announce-quarterly-sales-of-3-57-million.html.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.